Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Biopharmaceutical Manufacturing Market Witnessing a Shift Towards Contract Manufacturing Organisations

Posted on: 15 Sep 16

Biopharmaceutical manufacturing is a cost-intensive and time taking process which requires expertise. In order to reduce manufacturing costs, biopharmaceutical companies are outsourcing their manufacturing operations to Contract Manufacturing Organisations (CMOs).

According to IMARC’s study “Global Biopharmaceutical Manufacturing Market Report 2016-2021”, the global biopharmaceutical manufacturing capacity has grown at a CAGR of more than 6% during 2008-2015. Compared to pharmaceutical products which are synthesized chemically, biopharmaceuticals are manufactured from biological sources. However, their development and production is a complex and delicate process involving superior technology and highly skilled work force. The production facilities are also more expensive and require more time to set-up as compared to small molecule drugs. These facilities are also significantly costlier to run and involve long process durations, low yields and expensive raw materials. The global biopharmaceutical manufacturing market is currently being driven by improved technologies and processes, emergence of biosimilars, entry of new players, growing demand for vaccines & biologic drugs worldwide and an increase in the global ageing population.

Currently, biopharmaceuticals represent the fastest developing segment of the global pharmaceutical market. The increasing popularity of biopharmaceuticals and high returns have led to a number of companies developing and manufacturing them. In most cases biopharmaceuticals are manufactured in-house by innovator companies. This trend, however, is changing and shifting towards contract manufacturing organizations (CMOs).  This trend is currently being driven both by significant cost savings and the recognition that contract manufacturing organizations (CMOs) can be more effective, innovative and efficient partners with specific capabilities that can even exceed those available in-house.

Browse full report at

IMARC’s report provides a detailed analysis of the biopharmaceutical manufacturing market. The report has segmented the market on the basis of the cell culture used for manufacturing biopharmaceuticals. Findings from the report suggest that mammalian cell culture currently dominates the global biopharmaceutical production. The report has also studied the biopharmaceuticals manufacturing market on the basis of class. The classes covered in the report include – monoclonal antibodies, recombinant proteins, interferons, granulocyte colony-stimulating factor (G-CSF),erythropoietin, recombinant human insulin, vaccines and human growth hormones (HGH).

On the basis of geographical segmentation, the report has covered Asia, Europe and North America. Currently, North America dominates the global biopharmaceuticals manufacturing market accounting for nearly half of the total market share followed by Europe and Asia. Asia, on the other hand, represents the fastest growing market for biopharmaceutical manufacturing. The report has also analysed the competitive landscape of the global biopharmaceutical manufacturing market. Some of the key players covered by the report include – Roche Ltd., Amgen, Novo Nordisk, AbbVie, Sanofi S.A, Johnson & Johnson, Pfizer, Merck & Co., Eli Lilly and Company, and Biogen Idec, Inc.

Enquiry for sample report or more details, click here:

For more information:

Editor's Details

Kanika Sharma

Last updated on: 15/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.